Novo Nordisk A/S Common Stock (NVO)

These two underappreciated dividend payers offer above-average yields and relatively rapid payout growth.

Trump’s plan to cover weight loss drugs under Medicaid programs and Medicare Part D plans to could be a major tailwind for LLY and NVO, despite tarrif threats.

Stocks were higher for the week as investors overlooked tariff uncertainty, but the bulls may get tested by next week's data on inflation and retail sales

The telehealth platform is growing quickly but is in the middle of a legal battle.

It looked good next to a company that has been stealing its thunder lately.

Weight loss drug goliath Eli Lilly just tanked despite posting impressive Q2 results. See what drove the decline and whether the market reaction is overdone.

The company is using litigation to protect sales of its most popular treatments.

Investors shouldn't expect a V-shaped recovery.

Novo Nordisk A/S climbed 3.72% during Friday's pre-market trading session, after rival Eli Lily 's Phase 3 ATTAIN-1 trial for obesity drug, orforglipron trailed the Danish drug giant's semaglutide.

NOVO-NORDISK A/S (NVO) offers affordable growth with strong revenue, earnings growth, and fair valuation, making it a top pick for balanced investors.

These Vanguard index funds offer diversified exposure to many of the most influential stocks in the world.

Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the day, following the release of late-stage study results for its highly anticipated oral weight-loss drug, orforglipron. While the drug met its primary

Eli Lilly's obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising trial updates.

An analyst called the unexpected flop a "once-in-a-blue-moon" occasion for Eli Lilly's dominant weight-loss franchise.

Eli Lilly shares fell after orforglipron's Phase 3 data showed less weight loss than rival drugs, despite a strong Q2 earnings beat and raised guidance.

The Danish pharmaceutical company is fighting a competitive war on several fronts.

A surge in private market investment has investors wondering: Is it time to bet bigger on biotech?

Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021.

Competition is hurting sales of critical products.

The company is struggling with several headwinds as it works to develop its obesity plan.

Between battered industries and overlooked opportunities, plenty of dividend-paying companies have slipped.

The company says it's working to ensure patients only receive semaglutide produced by Novo Nordisk.

Novo Nordisk reported Q2 sales of $11.7 billion, missing consensus. Sales increased by 13% in Danish kroner, driven by GLP-1 diabetes and obesity care sales.

Tech entrepreneur Bryan Johnson refutes claims that Novo Nordisk AS's Ozempic demonstrates anti-aging properties.